NASDAQ:REPL - Replimune Group Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $56.00
Forecasted Upside: 62.08 %
Number of Analysts: 8
Breakdown:
0 Sell Ratings
0 Hold Ratings
8 Buy Ratings
0 Strong Buy Ratings

^$34.55 As of 06/15/2021 01:00 AM ET

▼ -0.12 (-0.35%)

1 month | 3 months | 12 months

Get New Replimune Group Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for REPL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for REPL

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$56.00

▲ +62.08% Upside Potential

This price target is based on 8 analysts offering 12 month price targets for Replimune Group in the last 3 months. The average price target is $56.00, with a high forecast of $67.00 and a low forecast of $48.00. The average price target represents a 62.08% upside from the last price of $34.55.

Buy

The current consensus among 8 polled investment analysts is to buy stock in Replimune Group. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
5 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

12/24/2019

0 strong buy ratings
5 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/23/2020

0 strong buy ratings
7 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/21/2020

0 strong buy ratings
7 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

9/19/2020

0 strong buy ratings
9 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

12/18/2020

0 strong buy ratings
9 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/18/2021

0 strong buy ratings
9 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/17/2021

0 strong buy ratings
8 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/16/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
2/5/2021	HC Wainwright	Boost Price Target	Buy	$58.00 ➝ $60.00	Medium	i Rating by R. Burns at HC Wainwright
2/4/2021	SVB Leerink	Lower Price Target	Outperform	$57.00 ➝ $56.00	Medium	i
11/17/2020	BTIG Research	Initiated Coverage	Buy	$60.00	High	i
11/10/2020	HC Wainwright	Boost Price Target	Buy	$54.00 ➝ $58.00	Low	i Rating by R. Burns at HC Wainwright
11/6/2020	BMO Capital Markets	Boost Price Target	Outperform	$51.00 ➝ $57.00	High	i
11/2/2020	Jefferies Financial Group	Initiated Coverage	Buy	$67.00	High	i
10/15/2020	BMO Capital Markets	Boost Price Target	Positive ➝ Outperform	$40.00 ➝ $51.00	High	i
10/15/2020	Barclays	Boost Price Target	Overweight	$29.00 ➝ $50.00	High	i Rating by Peter Lawson at Barclays PLC
10/15/2020	HC Wainwright	Upgrade	Neutral ➝ Buy	$25.00 ➝ $54.00	High	i Rating by R. Burns at HC Wainwright
10/15/2020	SVB Leerink	Boost Price Target	Outperform	$27.00 ➝ $44.00	High	i
10/14/2020	Roth Capital	Boost Price Target	Buy	$30.00 ➝ $50.00	High	i
10/14/2020	Chardan Capital	Boost Price Target	Buy	$30.00 ➝ $48.00	High	i Rating by Geulah Livshits at Chardan Capital
8/7/2020	Chardan Capital	Reiterated Rating	Buy	$30.00	High	i Rating by Geulah Livshits at Chardan Capital
8/7/2020	SVB Leerink	Boost Price Target	Outperform	$25.00 ➝ $27.00	Low	i
7/1/2020	HC Wainwright	Reiterated Rating	Buy ➝ Neutral	$25.00	High	i Rating by Robert Burns at HC Wainwright
6/4/2020	BMO Capital Markets	Boost Price Target	Outperform	$31.00 ➝ $40.00	High	i
6/4/2020	HC Wainwright	Reiterated Rating	Buy	$24.00 ➝ $25.00	High	i Rating by R. Burns at HC Wainwright
6/4/2020	Barclays	Boost Price Target	Overweight	$21.00 ➝ $25.00	High	i Rating by Peter Lawson at Barclays PLC
6/4/2020	Chardan Capital	Reiterated Rating	Buy	$29.00	High	i Rating by Geulah Livshits at Chardan Capital
6/3/2020	Wedbush	Reiterated Rating	Outperform		Medium	i Rating by R. Driscoll at Wedbush
5/4/2020	Barclays	Initiated Coverage	Overweight	$21.00	High	i Rating by Peter Lawson at Barclays PLC
2/13/2020	Chardan Capital	Reiterated Rating	Buy	$28.00	Low	i Rating by Geulah Livshits at Chardan Capital
1/21/2020	HC Wainwright	Reiterated Rating	Buy	$26.00 ➝ $24.00	High	i Rating by Ram Selvaraju at HC Wainwright
11/20/2019	Wedbush	Lower Price Target	Outperform	$30.00 ➝ $12.50	Medium	i
11/11/2019	Roth Capital	Boost Price Target	Buy	$20.00 ➝ $30.00	Low	i Rating by T. Butler at Roth Capital
10/24/2019	Chardan Capital	Reiterated Rating	Buy	$28.00	Low	i Rating by Geulah Livshits at Chardan Capital
10/15/2019	Chardan Capital	Set Price Target	Buy	$28.00	High	i Rating by Geulah Livshits at Chardan Capital
9/30/2019	HC Wainwright	Reiterated Rating	Buy	$26.00	Low	i Rating by R. Selvaraju at HC Wainwright
9/4/2019	Roth Capital	Initiated Coverage	Buy	$20.00	High	i Rating by T. Butler at Roth Capital
8/15/2019	Chardan Capital	Reiterated Rating	Buy	$28.00	Medium	i
7/23/2019	Chardan Capital	Initiated Coverage	Buy ➝ Buy	$28.00	Low	i
7/12/2019	JPMorgan Chase & Co.	Upgrade	Neutral ➝ Overweight	$27.00 ➝ $26.00	Low	i
7/8/2019	HC Wainwright	Initiated Coverage	Buy ➝ Buy	$26.00	Low	i Rating by R. Selvaraju at HC Wainwright
4/24/2019	Wedbush	Initiated Coverage	Outperform ➝ Outperform	$24.00	High	i Rating by R. Driscoll at Wedbush
1/23/2019	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral		High	i
8/14/2018	SVB Leerink	Initiated Coverage	Outperform	$25.00	Low	i Rating by J. Chang at SVB Leerink LLC
8/14/2018	BMO Capital Markets	Initiated Coverage	Outperform	$31.00	Low	i
8/14/2018	JPMorgan Chase & Co.	Initiated Coverage	Overweight	$26.00	Low	i

(Data available from 6/16/2016 forward)

Replimune Group, Inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Today's Range

Now: $34.55

$33.23

$34.77

50 Day Range

MA: $33.93

$28.50

$38.97

52 Week Range

Now: $34.55

$18.40

$54.85

Volume

293,633 shs

Average Volume

366,348 shs

Market Capitalization

$1.61 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.53

Frequently Asked Questions

What sell-side analysts currently cover shares of Replimune Group?

The following Wall Street research analysts have issued research reports on Replimune Group in the last twelve months: Barclays PLC, BMO Capital Markets, BTIG Research, Chardan Capital, HC Wainwright, Jefferies Financial Group Inc., Roth Capital, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for REPL.

What is the current price target for Replimune Group?

8 Wall Street analysts have set twelve-month price targets for Replimune Group in the last year. Their average twelve-month price target is $56.00, suggesting a possible upside of 62.1%. Jefferies Financial Group Inc. has the highest price target set, predicting REPL will reach $67.00 in the next twelve months. Chardan Capital has the lowest price target set, forecasting a price of $48.00 for Replimune Group in the next year.
View the latest price targets for REPL.

What is the current consensus analyst rating for Replimune Group?

Replimune Group currently has 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe REPL will outperform the market and that investors should add to their positions of Replimune Group.
View the latest ratings for REPL.

What other companies compete with Replimune Group?

Other companies that are similar to Replimune Group include Halozyme Therapeutics, Vir Biotechnology, Beam Therapeutics, Recursion Pharmaceuticals, Adaptive Biotechnologies, Twist Bioscience, Sana Biotechnology, Kodiak Sciences, Abcam, SpringWorks Therapeutics, Ablynx, Iovance Biotherapeutics, Allogene Therapeutics, Relay Therapeutics and Bavarian Nordic A/S.

How do I contact Replimune Group's investor relations team?

Replimune Group's physical mailing address is 500 Unicorn Park, WOBURN MA, 01801. The company's listed phone number is 781-222-9600 and its investor relations email address is [email protected] The official website for Replimune Group is www.replimune.com.